OncLive® On Air S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA
May 5, 2025
In this engaging discussion, Dr. Anna C. Pavlick, a professor at Weill Cornell Medicine and a pioneer in cutaneous oncology, dives into the promising RP1 plus nivolumab combo for advanced melanoma. She highlights key findings from the IGNITE trial, showcasing its potential for patients who haven't responded to previous treatments. Dr. Pavlick emphasizes the combination's strong efficacy and low toxicity, while also touching on the exciting future of oncolytic viruses in melanoma therapy. A must-listen for anyone interested in cutting-edge cancer treatments!
AI Snips
Chapters
Transcript
Episode notes
Unmet Needs in Melanoma Treatment
- About 30 to 40% of metastatic melanoma patients have limited treatment options after immunotherapy and targeted therapy resistance.
- RP1 oncolytic virus offers a novel approach by triggering stronger immune responses and immunogenic cell death.
Rationale for IGNITE Trial
- Enroll patients progressing after anti-PD therapy on RP1 plus nivolumab trials to leverage immune system priming.
- Inject local tumors with RP1 to stimulate broader immune responses including distant tumors.
Durable Responses in Resistant Melanoma
- 31% of advanced melanoma patients resistant to immunotherapy responded to RP1 plus nivolumab.
- Responses including 12% complete remissions were durable, lasting at least two years in many cases.